capecitabine + lapatinib + trastuzumab
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastases, Brain
Conditions
Metastases, Brain
Trial Timeline
Apr 14, 2009 → Mar 22, 2018
NCT ID
NCT00820222About capecitabine + lapatinib + trastuzumab
capecitabine + lapatinib + trastuzumab is a phase 3 stage product being developed by Novartis for Metastases, Brain. The current trial status is completed. This product is registered under clinical trial identifier NCT00820222. Target conditions include Metastases, Brain.
What happened to similar drugs?
0 of 11 similar drugs in Metastases, Brain were approved
Approved (0) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00820222 | Phase 3 | Completed |
Competing Products
20 competing products in Metastases, Brain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2780301 | Eli Lilly | Phase 1 | 29 |
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 39 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 27 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 35 |
| Denosumab + Zoledronic Acid | Daiichi Sankyo | Phase 3 | 40 |
| Leuprorelin Acetate | Astellas Pharma | Phase 3 | 44 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 42 |
| ALIMTA + folic acid + multi-vitamins | Eli Lilly | Phase 1 | 29 |
| Merestinib | Eli Lilly | Phase 1 | 21 |
| LY2584702 + Erlotinib + Everolimus | Eli Lilly | Phase 1 | 21 |
| Veliparib + Placebo | AbbVie | Phase 2 | 35 |
| temozolomide | Merck | Phase 2 | 27 |
| Vorinostat | Merck | Phase 1 | 29 |
| Pembrolizumab | Merck | Phase 2 | 39 |
| EMD 525797 | Merck | Phase 1 | 29 |
| Temozolomide | Merck | Phase 2 | 35 |
| cabazitaxel + lapatinib | Novartis | Phase 2 | 27 |
| BKM120 + capecitabine + Trastuzumab | Novartis | Phase 2 | 35 |
| Zoledronic acid | Novartis | Phase 3 | 40 |
| zoledronic acid | Novartis | Phase 1 | 29 |